Entrada Therapeutics (TRDA) risk factors

Item 1A of every Entrada Therapeutics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.

Open TRDA in Gloom →

Entrada Therapeutics' chart, financials and news, free in your browser.Open TRDA in Gloom →

FY2025 10-K risk factors
87 risks14 new12 dropped25 reworded
Entrada faces heavy regulatory scrutiny for its EEV-based muscular dystrophy candidates like ENTR-601-44.
Filed Feb 26, 2026
FY2024 10-K risk factors
85 risks
Entrada Therapeutics faces substantial development and financing risks driven by its reliance on unapproved novel EEV technology and third-party manufacturers.
Filed Feb 27, 2025